JP2001514858A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2001514858A5 JP2001514858A5 JP2000508817A JP2000508817A JP2001514858A5 JP 2001514858 A5 JP2001514858 A5 JP 2001514858A5 JP 2000508817 A JP2000508817 A JP 2000508817A JP 2000508817 A JP2000508817 A JP 2000508817A JP 2001514858 A5 JP2001514858 A5 JP 2001514858A5
- Authority
- JP
- Japan
- Prior art keywords
- conjugate
- region
- protein
- host cell
- expression vector
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 description 4
- 239000013604 expression vector Substances 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 108700031308 Antennapedia Homeodomain Proteins 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 230000004568 DNA-binding Effects 0.000 description 1
- 102100039869 Histone H2B type F-S Human genes 0.000 description 1
- 108010048671 Homeodomain Proteins Proteins 0.000 description 1
- 102000009331 Homeodomain Proteins Human genes 0.000 description 1
- 101001035372 Homo sapiens Histone H2B type F-S Proteins 0.000 description 1
- 208000026350 Inborn Genetic disease Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 238000001261 affinity purification Methods 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 108091006104 gene-regulatory proteins Proteins 0.000 description 1
- 102000034356 gene-regulatory proteins Human genes 0.000 description 1
- 208000016361 genetic disease Diseases 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB9718609.2 | 1997-09-02 | ||
| GBGB9718609.2A GB9718609D0 (en) | 1997-09-02 | 1997-09-02 | Fusion protein |
| PCT/GB1998/002628 WO1999011809A1 (en) | 1997-09-02 | 1998-09-02 | Conjugates that contain the homeodomain of antennapedia |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2001514858A JP2001514858A (ja) | 2001-09-18 |
| JP2001514858A5 true JP2001514858A5 (https=) | 2006-01-05 |
Family
ID=10818419
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000508817A Pending JP2001514858A (ja) | 1997-09-02 | 1998-09-02 | アンテナペディアのホメオドメインを含むコンジュゲート |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US7968512B2 (https=) |
| EP (1) | EP1009847A1 (https=) |
| JP (1) | JP2001514858A (https=) |
| AU (1) | AU737829B2 (https=) |
| BR (1) | BR9811744A (https=) |
| CA (1) | CA2301157A1 (https=) |
| GB (1) | GB9718609D0 (https=) |
| IL (2) | IL134602A0 (https=) |
| NZ (1) | NZ503007A (https=) |
| WO (1) | WO1999011809A1 (https=) |
Families Citing this family (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2001505055A (ja) * | 1996-12-02 | 2001-04-17 | ウエイク・フオレスト・ユニバーシテイ | Ｈｉｖ感染の治療としてのｈｉｖコレセプターの不活性化 |
| CA2314267A1 (en) * | 1997-12-10 | 1999-06-17 | Washington University | Anti-pathogen system and methods of use thereof |
| GB9814527D0 (en) * | 1998-07-03 | 1998-09-02 | Cyclacel Ltd | Delivery system |
| DK1129064T3 (da) | 1998-11-12 | 2008-04-28 | Invitrogen Corp | Transfektionsreagenser |
| IL142869A0 (en) | 1998-11-13 | 2002-03-10 | Cyclacel Ltd | Transport vectors |
| AU762006B2 (en) | 1998-12-24 | 2003-06-19 | Ucb | Peptidic product, process and composition |
| WO2000058488A2 (en) * | 1999-03-31 | 2000-10-05 | Invitrogen Corporation | Delivery of functional protein sequences by translocating polypeptides |
| US6773920B1 (en) | 1999-03-31 | 2004-08-10 | Invitrogen Corporation | Delivery of functional protein sequences by translocating polypeptides |
| US6372494B1 (en) | 1999-05-14 | 2002-04-16 | Advanced Tissue Sciences, Inc. | Methods of making conditioned cell culture medium compositions |
| EP1118668A1 (en) * | 2000-01-07 | 2001-07-25 | ARTEMIS Pharmaceuticals GmbH | Transduction of recombinases for inducible gene targeting |
| EP1244796A2 (en) * | 2000-01-07 | 2002-10-02 | ARTEMIS Pharmaceuticals GmbH | Transduction of recombinases for inducible gene targeting |
| GB0003284D0 (en) * | 2000-02-15 | 2000-04-05 | Secr Defence Brit | Anti-viral therapy |
| US20040110928A1 (en) * | 2000-04-12 | 2004-06-10 | Andrea Crisanti | Peptide conjugates for drug delivery |
| DE10027777A1 (de) * | 2000-06-07 | 2001-12-13 | Otogene Ag | Transfektionsverfahren |
| GB0015090D0 (en) * | 2000-06-20 | 2000-08-09 | Implyx Ltd | Gene-activating conjugates |
| KR100374050B1 (ko) * | 2000-07-26 | 2003-03-03 | 최수영 | 세포침투성 융합단백질, 이를 코딩하는 재조합폴리뉴클레오타이드 및 발현벡터 |
| US20030027335A1 (en) * | 2000-09-07 | 2003-02-06 | Ruley H. Earl | Genome engineering by cell-permeable DNA site-specific recombinases |
| US6472176B2 (en) * | 2000-12-14 | 2002-10-29 | Genvec, Inc. | Polynucleotide encoding chimeric protein and related vector, cell, and method of expression thereof |
| CA2367636C (en) | 2001-04-12 | 2010-05-04 | Lisa Mckerracher | Fusion proteins |
| US7442686B2 (en) | 2001-04-12 | 2008-10-28 | Bioaxone Therapeutique Inc. | Treatment of macular degeneration with ADP-ribosyl transferase fusion protein therapeutic compositions |
| EP1406573A4 (en) * | 2001-06-07 | 2005-03-30 | Skinmedica Inc | CONDITIONED CELL CULTURE MEDIA AND ITS USES |
| GB0124391D0 (en) * | 2001-10-11 | 2001-11-28 | Gene Expression Technologies L | Control of gene expression |
| US20050136040A1 (en) * | 2001-10-11 | 2005-06-23 | Imperial College Innovations Limited | Control of gene expression using a complex of an oligonucleotide and a regulatory peptide |
| ITRM20030376A1 (it) | 2003-07-31 | 2005-02-01 | Univ Roma | Procedimento per l'isolamento e l'espansione di cellule staminali cardiache da biopsia. |
| US11660317B2 (en) | 2004-11-08 | 2023-05-30 | The Johns Hopkins University | Compositions comprising cardiosphere-derived cells for use in cell therapy |
| DE102007041655A1 (de) | 2007-09-03 | 2009-03-05 | Medicyte Gmbh | Vermehrung von primären Zellen und deren Verwendung |
| US8119366B2 (en) | 2007-10-05 | 2012-02-21 | Trojan Technologies, Ltd. | Antennapedia-dominant negative mastermind-like construct |
| AU2010238346A1 (en) | 2009-04-14 | 2011-11-03 | Trojan Technologies Ltd. | Therapeutic Antennapedia-antibody molecules and methods of use thereof |
| US9845457B2 (en) | 2010-04-30 | 2017-12-19 | Cedars-Sinai Medical Center | Maintenance of genomic stability in cultured stem cells |
| DE102010041958A1 (de) | 2010-10-04 | 2012-04-05 | Medicyte Gmbh | Geeignete Hepatozyten für in-vitro Genotoxitätstests |
| US20140296154A1 (en) * | 2011-05-06 | 2014-10-02 | Yale University | Method of preventing development of psoriatic lesions |
| ES2633343T3 (es) * | 2011-06-13 | 2017-09-20 | The Board Of Trustees Of The University Of Illionis | Composiciones de péptidos y métodos para tratar lesión pulmonar, asma, anafilaxis, angioedema, síndromes de permeabilidad vascular sistémica y congestión nasal |
| US9937242B2 (en) | 2012-04-09 | 2018-04-10 | Case Western Reserve University | Compositions and methods for inhibiting the activity of LAR family phosphatases |
| WO2013184527A1 (en) | 2012-06-05 | 2013-12-12 | Capricor, Inc. | Optimized methods for generation of cardiac stem cells from cardiac tissue and their use in cardiac therapy |
| AU2013302799B2 (en) | 2012-08-13 | 2018-03-01 | Cedars-Sinai Medical Center | Exosomes and micro-ribonucleic acids for tissue regeneration |
| CA2915296A1 (en) * | 2013-06-11 | 2015-02-26 | Portage Pharmaceuticals Ltd. | Structure, manufacturing and uses of human-derived cell-permeable peptides conjugated with specific biologically active cargo peptides |
| EP2927685A1 (en) | 2014-04-02 | 2015-10-07 | Medicyte GmbH | Suitable hepatocytes for in-vitro hepatitis tests |
| WO2016011203A1 (en) | 2014-07-15 | 2016-01-21 | Life Technologies Corporation | Compositions with lipid aggregates and methods for efficient delivery of molecules to cells |
| CA2962444C (en) | 2014-10-03 | 2023-09-05 | Cedars-Sinai Medical Center | Cardiosphere-derived cells and exosomes secreted by such cells in the treatment of muscular dystrophy |
| BR112017018665A2 (pt) | 2015-03-02 | 2018-04-24 | The Board Of Trustees Of The University Of Illinois | peptídeos para inibição de angiogênese |
| EP3402543B1 (en) | 2016-01-11 | 2021-09-08 | Cedars-Sinai Medical Center | Cardiosphere-derived cells and exosomes secreted by such cells in the treatment of heart failure with preserved ejection fraction |
| JP2019513752A (ja) | 2016-04-07 | 2019-05-30 | ケース ウエスタン リザーブ ユニバーシティ | 神経変性疾患を治療するためのｔｄｐ−４３のミトコンドリア局在化阻害剤 |
| WO2017210652A1 (en) | 2016-06-03 | 2017-12-07 | Cedars-Sinai Medical Center | Cdc-derived exosomes for treatment of ventricular tachyarrythmias |
| US11541078B2 (en) | 2016-09-20 | 2023-01-03 | Cedars-Sinai Medical Center | Cardiosphere-derived cells and their extracellular vesicles to retard or reverse aging and age-related disorders |
| EP4699658A2 (en) | 2017-04-19 | 2026-02-25 | Cedars-Sinai Medical Center | Methods and compositions for treating skeletal muscular dystrophy |
| CN111093684A (zh) | 2017-07-11 | 2020-05-01 | 凯斯西储大学 | 用于治疗髓鞘病症的组合物和方法 |
| US11660355B2 (en) | 2017-12-20 | 2023-05-30 | Cedars-Sinai Medical Center | Engineered extracellular vesicles for enhanced tissue delivery |
| US12146137B2 (en) | 2018-02-05 | 2024-11-19 | Cedars-Sinai Medical Center | Methods for therapeutic use of exosomes and Y-RNAS |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2739621B1 (fr) * | 1995-10-05 | 1997-12-05 | Centre Nat Rech Scient | Peptides utilisables comme vecteurs pour l'adressage intracellulaire de molecules actives |
-
1997
- 1997-09-02 GB GBGB9718609.2A patent/GB9718609D0/en active Pending
-
1998
- 1998-09-02 CA CA002301157A patent/CA2301157A1/en not_active Abandoned
- 1998-09-02 JP JP2000508817A patent/JP2001514858A/ja active Pending
- 1998-09-02 IL IL13460298A patent/IL134602A0/xx active IP Right Grant
- 1998-09-02 AU AU88776/98A patent/AU737829B2/en not_active Ceased
- 1998-09-02 WO PCT/GB1998/002628 patent/WO1999011809A1/en not_active Ceased
- 1998-09-02 BR BR9811744-0A patent/BR9811744A/pt not_active Application Discontinuation
- 1998-09-02 NZ NZ503007A patent/NZ503007A/xx not_active IP Right Cessation
- 1998-09-02 EP EP98940453A patent/EP1009847A1/en not_active Withdrawn
-
2000
- 2000-02-17 IL IL134602A patent/IL134602A/en not_active IP Right Cessation
-
2004
- 2004-02-27 US US10/789,403 patent/US7968512B2/en not_active Expired - Lifetime
-
2011
- 2011-06-24 US US13/168,167 patent/US8735340B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2001514858A5 (https=) | ||
| JP2002513556A5 (https=) | ||
| JP2002527052A5 (https=) | ||
| JP3659261B2 (ja) | 組換体タンパク質の多機能性複合体への標的化ヘテロ結合 | |
| JP2004503213A5 (https=) | ||
| KR100484084B1 (ko) | 키메라성 폴리펩타이드, 이의 제조 방법 및 용도 | |
| JP2008505985A5 (https=) | ||
| JP2003503366A5 (https=) | ||
| WO1996004385A3 (en) | Purified hepatitis c virus envelope proteins for diagnostic and therapeutic use | |
| JP2003510366A5 (https=) | ||
| WO2006056464A3 (en) | Compound with affinity for the cytotoxic t lymphocyte-associated antigen (ctla-4) | |
| JPH07506821A (ja) | ジフテリア毒素受容体結合領域 | |
| JPH11253181A (ja) | 組換えシュードモナスエクソトキシン：低副作用の活性イムノトキシンの構造 | |
| JP2002536417A5 (https=) | ||
| WO2003046560B1 (en) | Self-assembly molecules | |
| JP2004515575A5 (https=) | ||
| JPWO2021116462A5 (https=) | ||
| JP2003530360A (ja) | 薬剤送達のためのペプチド複合体 | |
| JP2001526242A5 (https=) | ||
| CA2392202A1 (en) | Constructs for delivery of therapeutic agents to neuronal cells | |
| WO2002020561A1 (en) | Novel polypeptides and anti-hiv drugs containing the same | |
| CA2311648A1 (en) | Ifnar2/ifn complex | |
| WO2003051912A3 (en) | Purified hepatitis c virus envelope proteins for diagnostic and therapeutic use | |
| CN115057938A (zh) | 抗新型冠状病毒人源化多价结合蛋白及其应用 | |
| JPS6299399A (ja) | ヒトγ−インタ−フエロンの生物活性誘導体 |